There’s been so much stem cell news recently, I haven’t written a lot about the other major breakthrough area in medicine. That is, of course, RNA interference (RNAi). So I’d like to rectify that oversight.

Laura Cadden says Aastrom Biosciences, Inc. (NASDAQ:ASTM) is one of the hottest biotech stocks priced under $5. The company hopes to use its proprietary Tissue Repair Cell (TRC) technology to revolutionise treatment for heart disease. And it is making good progress through the trial phases. Laura says Aastrom is poised to make 20% gains in six months

New breakthroughs in adult stem cell technology offer staggering implications for medical science, says Patrick Cox. And a massive opportunity for investors. As Big Pharma move in, Patrick says biotech companies involved in stem cell research and RNA technology could become the “investment of a lifetime.”

One of the biggest impacts of the new administration could be in stem cell research, according to Laura Cadden. Support for the use of embryonic stem cells would open a whole world of opportunity for specialist biotech firms. Laura picks 5 small-cap biotech stocks that would make huge gains on new stem cell legislation.